Dr. John Cush RheumNow
7 years 9 months ago
Chronic Urticaria associated with a 23% higher risk of osteoporosis, irrespective of steroid use. Population study from Israel compared 11,944 Chr urticaria w/ 59,829 controls. (HR = 1.23, 95% CI 1.10–1.37, p <0.001) https://t.co/eSq4BPV2J4
A systematic review and network meta-analysis of 47 randomized clinical trials in knee osteoarthritis finds uncertainty around estimates of effect size for pain scores thereby casting uncertainty over the long-term efficacy of medications for knee osteoarthritis.
Dr. John Cush RheumNow
7 years 9 months ago
Analysis of pegloticase clinical trial data shows that tophus resolution was achieved by 69.6% of 23 responders, 27.9% of 43 nonresponders, and 14.3% of 21 patients who received placebo. Resolution time = 9.9 mos. https://t.co/4Pu16t3BV8
Dr. John Cush RheumNow
7 years 9 months ago
Case series compared 247 pregnancies in IgA Vasculitis patients vs 556 control pregnancies showing IgA Vasculitis had no effect on fertility and did not induce flares. But IgAV had more spont. abortions, gestational HTN, preterm delivery. https://t.co/uJirv32UYc
Dr. John Cush RheumNow
7 years 9 months ago
“A goal without a plan is just a wish” ― Antoine de Saint-Exupéry
Dr. John Cush RheumNow
7 years 9 months ago
Pulmonary arterial hypertension is a very uncommon complication of Adult onset Stills disease - 4.8% of 41 AOSD pts developed PAH - often severe, with a mortality risk. https://t.co/XjyVArMNBl
Resolutions are about the new and better you. Yet most people discard resolutions, largely because they are satisfied with the status quo or are afraid of change. Here's are some suggestions for being the best version of yourself in 2019.
Both Gout and obstructive sleep apnea (OSA) comingle with a wide range of serious comorbidities. A matched retrospective cohort study from the UK Clinical Practice Research database shows those with OSA are at a higher risk of developing gout.
This report compared 15,879 patients with OSA versus 63,296 without; median follow‐up was 5.8 years.
Researchers from Yale have taken a novel approach and shown benefits when using tofacitinib in severe cutaneous sarcoidosis.A report in the NEJM describes a 48-year-old female woman who was previously unresponsive to multiple medications and had not received systemic glucocorticoids. She was treated with tofacitinib 10 mg twice-daily and clinically responded with near disappearance of her skin lesions..
Dr. John Cush RheumNow
7 years 9 months ago
The Downside of social media for patients: 1. if substituted for in-person support, 2. Misinformation, 3. Financial exploitation, 4. Information overload, 5. Compromised privacy https://t.co/FtPUkZespC
Dr. John Cush RheumNow
7 years 9 months ago
Social Media Benefits for patients: 1. Promotes engagement and empowerment 2. Provides psychosocial support, 3. informational support, 4. improves MD-patient relationship, 5. linical trials and cancer research education https://t.co/FtPUkZespC
Dr. John Cush RheumNow
7 years 9 months ago
Eli Lilly has announced that FDA has granted Fast Track designation to baricitinib, to be studied for the treatment of systemic lupus erythematosus (SLE). This drug is NOT FDA approved for lupus https://t.co/vK7i6AoKab
Dr. John Cush RheumNow
7 years 9 months ago
Congratulations to Professor Iain McInnes - he is one of the Queen's New Year Honours in Scotland, as a Commander of the Order of the British Empire (CBE), for his services to medicine. https://t.co/15bIELJiEj
Dr. John Cush RheumNow
7 years 9 months ago
Full text review of psoriatic arthritis for NPs and PAs https://t.co/hlLKLAQ9ZX
Dr. John Cush RheumNow
7 years 9 months ago
Abbvie has submitted its new JAK inhibitor, upadacitinib, to the FDA and EMA for consideration in moderate to severe rheumatoid arthritis https://t.co/49GspIEeYN

